English Deutsch Français Italiano Español Português 繁體中文 Bahasa Indonesia Tiếng Việt ภาษาไทย
All categories

2 answers

The recommendation was against approval. Too many chances that people would get the proper follow-up that drugs of that class require.

2007-12-15 15:32:36 · answer #1 · answered by ckm1956 7 · 0 0

No, it was not. The jury is still out on that one. A panel was to make a recommendation today to the FDA on the advisability of OTC Mevacor, but the FTC is going to review the recommendations.

2007-12-13 09:09:18 · answer #2 · answered by acermill 7 · 0 0

fedest.com, questions and answers